Associated Genetic Biomarkers
There are 3 clinical trials for B-cell neoplasm, of which 2 are open and 1 is completed or closed. Of the trials that contain B-cell neoplasm as an inclusion criterion, 3 are phase 1 (2 open).
ERBB2 is the most frequent gene inclusion criterion for B-cell neoplasm clinical trials .
Anti-cd20/cd3 monoclonal antibody xmab13676, cd19 chimeric antigen receptor t-cells, and gamma-secretase inhibitor ly3039478 are the most common interventions in B-cell neoplasm clinical trials.
Significant Genes in B-Cell Neoplasm
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for B-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and B-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) .
Gamma-secretase inhibitor ly3039478 and prednisone are the most frequent therapies in B-cell neoplasm trials with ERBB2 mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.